211 related articles for article (PubMed ID: 37116489)
21. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.
Boelaars K; Goossens-Kruijssen L; Wang D; de Winde CM; Rodriguez E; Lindijer D; Springer B; van der Haar Àvila I; de Haas A; Wehry L; Boon L; Mebius RE; van Montfoort N; Wuhrer M; den Haan JMM; van Vliet SJ; van Kooyk Y
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37940346
[TBL] [Abstract][Full Text] [Related]
22. A novel dual mechanism-of-action bispecific PD-1-IL-2v armed by a "βγ-only" interleukin-2 variant.
Jiang Y; Chen C; Liu Y; Wang R; Feng C; Cai L; Chang S; Zhao L
Front Immunol; 2024; 15():1369376. PubMed ID: 38638426
[TBL] [Abstract][Full Text] [Related]
23. Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma.
Piper M; Van Court B; Mueller A; Watanabe S; Bickett T; Bhatia S; Darragh LB; Mayeda M; Nguyen D; Gadwa J; Knitz M; Corbo S; Morgan R; Lee JJ; Dent A; Goodman K; Messersmith W; Schulick R; Del Chiaro M; Zhu Y; Kedl RM; Lenz L; Karam SD
Clin Cancer Res; 2022 Mar; 28(5):1013-1026. PubMed ID: 34862244
[TBL] [Abstract][Full Text] [Related]
24. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
25. IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25
Wu W; Chia T; Lu J; Li X; Guan J; Li Y; Fu F; Zhou S; Feng Y; Deng J; Zou J; Sun J; Yao Y; Ling X; Wu Z; Zhang Y; Xu J; Wang F; Liang X; Wu M; Liu H; Chen B; He K
Nat Cancer; 2023 Sep; 4(9):1309-1325. PubMed ID: 37550516
[TBL] [Abstract][Full Text] [Related]
26. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
27. A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions.
Enzler T; Shi J; McGue J; Griffith BD; Sun L; Sahai V; Nathan H; Frankel TL
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474199
[TBL] [Abstract][Full Text] [Related]
28. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
29. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.
Ye J; Gavras NW; Keeley DC; Hughson AL; Hannon G; Vrooman TG; Lesch ML; Johnston CJ; Lord EM; Belt BA; Linehan DC; Eyles J; Gerber SA
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142292
[TBL] [Abstract][Full Text] [Related]
30. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Somani VK; Zhang D; Dodhiawala PB; Lander VE; Liu X; Kang LI; Chen HP; Knolhoff BL; Li L; Grierson PM; Ruzinova MB; DeNardo DG; Lim KH
Gastroenterology; 2022 Jun; 162(7):2047-2062. PubMed ID: 35271824
[TBL] [Abstract][Full Text] [Related]
31. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
[TBL] [Abstract][Full Text] [Related]
32. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8
Rolig AS; Rose DC; McGee GH; Rubas W; Kivimäe S; Redmond WL
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35444059
[TBL] [Abstract][Full Text] [Related]
33. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.
Liu C; Cheng H; Luo G; Lu Y; Jin K; Guo M; Ni Q; Yu X
Int J Oncol; 2017 Aug; 51(2):686-694. PubMed ID: 28714519
[TBL] [Abstract][Full Text] [Related]
34. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Values of CD38
Zhang M; Yang J; Zhou J; Gao W; Zhang Y; Lin Y; Wang H; Ruan Z; Ni B
Immunol Invest; 2019 Jul; 48(5):466-479. PubMed ID: 30689488
[TBL] [Abstract][Full Text] [Related]
36. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
[TBL] [Abstract][Full Text] [Related]
37. ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression.
Burks J; Fleury A; Livingston S; Smith JP
Cancer Immunol Immunother; 2019 Dec; 68(12):2029-2039. PubMed ID: 31709456
[TBL] [Abstract][Full Text] [Related]
38. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
39. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate.
Merchant R; Galligan C; Munegowda MA; Pearce LB; Lloyd P; Smith P; Merchant F; To MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058325
[TBL] [Abstract][Full Text] [Related]
40. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]